Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Minodronate

Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_3757-3

Synonyms

Definition

Bisphosphonates are potent inhibitors of bone resorption and are widely used drugs for the treatment of osteoporosis, osteolytic bone metastasis, and tumor-associated hypercalcemia. These compounds have high affinity for calcium ions and therefore target bone mineral, where they are internalized by bone-resorbing osteoclasts and inhibit osteoclast function. Minodronate, a nitrogen-containing bisphosphonate, acts intracellularly by inhibiting farnesyl pyrophosphate synthase, thus leading to the inhibition of posttranslational prenylation of small molecular weight G proteins, which could also contribute to its antiresorptive activity on osteoclasts and its antitumor effects in vivo.

Characteristics

Minodronate is one of the...

Keywords

Vascular Endothelial Growth Factor Vascular Endothelial Growth Factor Expression Oral Squamous Cell Carcinoma Vascular Endothelial Growth Factor Signaling Vascular Endothelial Growth Factor Overexpression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Green JR, Clezardin P (2002) Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol 25:S3–S9PubMedCrossRefGoogle Scholar
  2. Yamagishi S, Abe R, Inagaki Y et al (2004) Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. Am J Pathol 165:1865–1874PubMedPubMedCentralCrossRefGoogle Scholar
  3. Yamagishi S, Matsui T, Nakamura K et al (2005) Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation. Int J Tissue React 27:189–195PubMedGoogle Scholar
  4. Yamagishi S, Nakamura K, Matsui T et al (2006) Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy. Med Hypotheses 66:273–275PubMedCrossRefGoogle Scholar
  5. Ylitalo R, Kalliovalkama J, Wu X et al (1998) Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro. Pharmacol Toxicol 83:125–131PubMedCrossRefGoogle Scholar

See Also

  1. (2012) AGEs. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 101. doi:10.1007/978-3-642-16483-5_140Google Scholar
  2. (2012) Angiogenic switch. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 186. doi:10.1007/978-3-642-16483-5_277Google Scholar
  3. (2012) Caspase-3. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 675. doi:10.1007/978-3-642-16483-5_874Google Scholar
  4. (2012) MCP-1. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 2192. doi:10.1007/978-3-642-16483-5_3576Google Scholar
  5. (2012) Prenylation. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 2984. doi:10.1007/978-3-642-16483-5_4726Google Scholar
  6. (2012) RAGE. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3163. doi:10.1007/978-3-642-16483-5_4939Google Scholar
  7. (2012) VCAM-1. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3905. doi:10.1007/978-3-642-16483-5_6170Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of Pathophysiology and Therapeutics of Diabetic Vascular ComplicationsKurume University School of MedicineKurumeJapan